USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS BY CARDIOLOGISTS SINCE THE RELEASE OF 2022 AHA/ACC/HFSA GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE

• 主要な著者: Gowtham R. Grandhi, MD MPH (著者), Rishav Adhikari, MD (著者), Erfan Tasdighi, MD (著者), Albert D. Osei, MD MPH (著者), Michael Khorsandi, MD (著者), Anurag Mehta, MD (著者), Michael Blaha, MD MPH (著者)
• フォーマット: 図書
• 出版事項: Elsevier, 2023-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Therapeutic Area: Heart Failure Background: Several studies have shown that most patients who are eligible for an Sodium-glucose Cotransporter-2 inhibitor (SGLT2i) are not receiving them and the proportion of prescriptions from cardiologists was very low (<2%) as of December 2020. Moreover, two S...